Table 2.
Comparison of clinical characteristics between cluster I (N = 20) and cluster II (N = 172).
| Cluster I | Cluster II | p-value | |
|---|---|---|---|
| Recipient age (years) | 52.0 ± 11.7 | 55.9 ± 11.6 | 0.16 |
| Donor age (years) | 47.2 ± 14.8 | 54.3 ± 15.2 | 0.05 |
| Recipient sex (male) | 7 (35.0%) | 126 (73.3%) | 0.0004 |
| Donor sex (male) a | 12 (60.0%) | 98 (58.0%) | 0.86 |
| Cold ischemia time (hours) a | 11.2 ± 5.8 | 11.9 ± 5.5 | 0.59 |
| Type of donor | 0.55 | ||
| - Circulatory death | 3 (15.0%) | 39 (22.7%) | |
| - Brain death | 15 (75.0%) | 124 (72.1%) | |
| - Living | 2 (10.0%) | 9 (5.2%) | |
| Repeat transplantation (yes) | 6 (30.0%) | 17 (9.9%) | 0.009 |
| Immunosuppressive regimen (TAC-MMF-CS) | 20 (100%) | 155 (90.1%) | 0.14 |
| Induction therapy | 12 (60.0%) | 54 (31.4%) | 0.01 |
| Polyoma viremia (positive) a | 0 (0%) | 15 (8.7%) | 0.20 |
| CMV viremia (positive) a | 0 (0%) | 9 (5.2%) | 0.34 |
| Serum C reactive protein, mg/L | 8.7 (1.8–25.3) | 10.3 (2.9–21.1) | 0.66 |
| eGFR, MDRD, mL/min | 17.7 ± 11.9 | 19.8 ± 13.2 | 0.49 |
| Proteinuria, g/g creatinine | 0.3 (0.2–1.1) | 0.5 (0.2–1.2) | 0.30 |
| Time after transplantation (days) | 11 (7–24) | 10 (7–23) | 0.53 |
| HLA-DSA at time of biopsy | 14 (70.0%) | 3 (1.7%) | <0.0001 |
| HLA-DSA at time of transplant | 14 (70.0%) | 3 (1.7%) | <0.0001 |
| De novo HLA-DSA | 2 (10.0%) | 0 (0%) | <0.0001 |
| Any rejection | 14 (70.0%) | 58 (33.7%) | <0.0001 |
| - Pure ABMR | 1 (5.0%) | 4 (2.3%) | |
| - Pure TCMR | 2 (10.0%) | 33 (19.2%) | |
| - Pure borderline changes | 3 (15.0%) | 19 (11.1%) | |
| - Mixed rejection | 8 (40.0%) | 2 (1.2%) | |
| Acute histological lesions | |||
| - Glomerulitis > 0 | 10 (50.0%) | 23 (13.4%) | <0.0001 |
| - Peritubular capillaritis > 0 a | 6 (30.0%) | 13 (7.8%) | 0.002 |
| - Tubulitis >0 | 16 (80.0%) | 112 (65.1%) | 0.18 |
| - Interstitial inflammation >0 | 11 (55.0%) | 40 (23.3%) | 0.002 |
| - Intimal arteritis >0 | 7 (35.0%) | 31 (18.0%) | 0.07 |
| - C4d ptc >1 a | 8 (40.0%) | 9 (5.4%) | <0.0001 |
| - Thrombi (yes) | 4 (20.0%) | 6 (3.5%) | 0.002 |
| - ABMRh (yes) | 9 (45.0%) | 14 (8.1%) | <0.0001 |
aMissing data: donor sex N = 3; cold ischemia time N = 3; peritubular capillaritis N = 5; C4d deposition ptc N = 6; polyoma viremia N = 6; CMV viremia N = 40.
TAC, tacrolimus; MMF, mycophenolate mofetil; CS, corticosteroids.
Significant differences are indicated in bold.